Laurus Labs (BOM:540222) Total Equity: ₹54,314 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,529.65
GF Value ₹705.30
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Laurus Labs Total Equity?

Laurus Labs BOM:540222 -1.79% 66 Total Equity is ₹54,314 Mil as of Mar. 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹705.30 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Laurus Labs's total equity for the quarter that ended in Mar. 2026 was ₹54,314 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Laurus Labs Total Equity Historical Data

* Premium members only.

The historical data trend for Laurus Labs's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs Total Equity Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33,590.50 40,486.60 41,155.70 46,025.20 54,313.60

Laurus Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46,025.20 0.00 49,335.30 0.00 54,313.60
BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Laurus Labs's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=105111.9-50798.3
=54,314

Laurus Labs's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=105111.9-50798.3
=54,314

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹54,314 Mil mean?
Laurus Labs (BOM:540222) has a Total Equity of ₹54,314 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Laurus Labs and its competitors.
Is Laurus Labs' Total Equity too high?
Laurus Labs' current Total Equity is ₹54,314 Mil. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Total Equity compare to ZTS and UTHR?
Laurus Labs' Total Equity of ₹54,314 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Laurus Labs and its competitors. Laurus Labs's current Total Equity is ₹54,314 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹705.30, compared to a current price of ₹1,529.65 — trading 116.9% above its estimated fair value. The current Total Equity is ₹54,314 Mil. Laurus Labs' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Total Equity is ₹54,314 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,529.65 is trading 116.9% above its estimated GF Value™ of ₹705.30. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Total Equity: ₹54,314 Mil
  • GF Value™: ₹705.30 vs. price of ₹1,529.65 (116.9% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,529.65
Price
₹705.30
GF Value